

Receipt date 08/01/2006

10580077 - GAU 21633

SEP 01 2006

PTO/SB/21 (09-04)

Approved for use through 07/31/2006.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/580,077
Filing Date	May 18, 2006
First Named Inventor	Pliura et al.
Art Unit	Not Yet Known
Examiner Name	Not Yet Known
Attorney Docket Number	RAM-PT015


ENCLOSURES (Check all that apply)

- | | | |
|---|--|--|
| <input type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Fee Attached
<input type="checkbox"/> Amendment/Reply
<input type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Extension of Time Request
<input type="checkbox"/> Express Abandonment Request
<input checked="" type="checkbox"/> Supplemental Information Disclosure Statement

<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)
<input type="checkbox"/> Licensing-related Papers
<input type="checkbox"/> Petition
<input type="checkbox"/> Petition to Convert to a Provisional Application
<input type="checkbox"/> Power of Attorney, Revocation
<input type="checkbox"/> Change of Correspondence Address
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Request for Refund
<input type="checkbox"/> CD, Number of CD(s) _____
<input type="checkbox"/> Landscape Table on CD | <input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
Form PTO-1449 with copies of references cited therein |
|---|--|--|


Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	VOLPE AND KOENIG, P.C.		
Signature			
Printed name	Stephen B. Schott		
Date	8/29/2006	Reg. No.	51,294

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Stephen B. Schott	Date	8/29/2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.H./

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the **PATENT APPLICATION** of:

Pliura et al.

Application No.: 10/580,077

Filed: May 18, 2006

For: STABLE LIPOSOME COMPOSITIONS
COMPRISING LIPOPHILIC AMINE
CONTAINING PHARMACEUTICAL AGENTS

Group: Not Yet Known

Examiner: Not Yet Known

Our File: RAM-PT015

Date: August 29, 2006

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Further to Applicants Duty of Disclosure pursuant to 37 C.F.R. §1.56, Applicants wish to bring to the Examiner's attention the material cited on the enclosed PTO-1449 form. Copies of the cited documents are enclosed.


Pursuant to 37 C.F.R. § 1.97(e)(1), the undersigned certifies that information contained in this Information Disclosure Statement was cited in an International Search Report, copy enclosed, in a corresponding International Application.

Applicant: Pliura et al.
Application No.: 10/580,077

It is respectfully requested that the Examiner consider these documents and return an initialed copy of the PTO-1449 form indicating his consideration of the cited materials.


Respectfully submitted,

Pliura et al.

By 
Stephen B. Schott
Registration No. 51,294
(215) 568-6400

Volpe and Koenig, P.C.
United Plaza, Suite 1600
30 South 17th Street
Philadelphia, PA 19103

SBS/TAB
Enclosures

 FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		ATTY. DOCKET NO. RAM-PT015		SERIAL NO. 10/580,077	
		APPLICANT Pliura et al.			
		FILING DATE May 18, 2006		GROUP Not Yet Known	
U.S. PATENT DOCUMENTS					
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS SUBCLASS FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS SUBCLASS TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
	AY	Comparison Between The Activities Of Cationic Amphiphilic Drugs To Affect Phospholipids-Membranes And To Depress Cardiac Function, Biochemical Pharmacology Vol., 38, No. 15, pp. 2487-2496, 1989; (See Entire Document)			
	AZ	Preparation Of Desmopressin-Containing Liposomes For Intranasal Deliver Controlled Release, 70, pp. 375-382, 2001; ; (See Entire Document)			
	BA	Biodistribution Of Liposome-Associated Bupivacaine After Extradural Administration To Rabbits British Journal of Anaesthesia, 75, pp. 319-325, 1995, (See Materials & Methods Section)			
	BB	Motor Blockade And Absence Of Local Nerve Toxicity Induced By Liposomal Bupivacaine Injected Into The Brachial Plexus Of Rabbits, Acta Anaesth, 46(1), pp. 19-24, 1995, (See Methods Section)			
	BC	Lipid Peroxidation Of Phosphatidylcholine Liposomes Depressed By The Calcium Channel Blockers Nifedipine And Verapamil And By The Antiarrhythmic-Antihypoxic Drug Stobadine, Biochim. Biophys. Acta, 1003, pp. 238-245, 1989, (See Entire Document)			
	BD	Antinociception And Side Effects Of Liposome-Encapsulated Anfentanil After Spinal Delivery In Rats Anesth. Analg., 79, pp. 778-786, 1994, (See Methods Section)			
	BE	Accumulation Of Doxorubicin And Other Lipophilic Amines Into Large Unilamellar Vesicles In Response To Transmembrane Ph Gradients, Biochim. Et. Biophys. Acta, 1149, pp. 329-338, 1993, (See Entire Document)			
	BF	Autoclaving of liposomes, Microencapsulation, 11(6), pp. 669-672, 1994, (See Entire Document)			
	BG	Sterilization Of Liposomes By Heat Treatment Pharmaceutical Research, 10(11), pp. 1591-1596, 1993, (See Entire Document)			
	BH	Possibility Of Heat Sterilization Of Liposomes Chem. Pharm. Bull., 39(4), pp. 1018-1022, 1991			

EXAMINER /Kelaginamane Hiriyanna/ (01/14/2010)	DATE CONSIDERED 01/14/2010
---	-------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.H./